Related references
Note: Only part of the references are listed.Physical Activity and Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Kara DiJoseph et al.
DIGESTIVE DISEASES AND SCIENCES (2023)
Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness
Jessica Dahmus et al.
DIGESTIVE DISEASES AND SCIENCES (2023)
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
Jonathan G. Stine et al.
HEPATOLOGY (2022)
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
Nobuharu Tamaki et al.
GUT (2022)
The role of FGF21 and its analogs on liver associated diseases
Kimia Falamarzi et al.
FRONTIERS IN MEDICINE (2022)
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon et al.
GUT (2021)
Effect of exercise on hepatic steatosis: Are benefits seen without dietary intervention? A systematic review andmeta-analysis
Callum John Baker et al.
JOURNAL OF DIABETES (2021)
FGF21 in obesity and cancer: New insights
Weiqin Lu et al.
CANCER LETTERS (2021)
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
Manal F. Abdelmalek et al.
CONTEMPORARY CLINICAL TRIALS (2021)
NAFLD and Physical Exercise: Ready, Steady, Go!
Maja Cigrovski Berkovic et al.
FRONTIERS IN NUTRITION (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison et al.
NATURE MEDICINE (2021)
Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort
Carolin Schneider et al.
JHEP REPORTS (2021)
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba et al.
GASTROENTEROLOGY (2020)
Simple resistance exercise decreases cytokeratin 18 and fibroblast growth factor 21 levels in patients with nonalcoholic fatty liver disease A retrospective clinical study
Atsushi Takahashi et al.
MEDICINE (2020)
Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy
Yu Gao et al.
REDOX BIOLOGY (2020)
Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity
Emir Tas et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH
Jonathan G. Stine et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study
Ilaria Croci et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2019)
FGF21 as Modulator of Metabolism in Health and Disease
Caterina Tezze et al.
FRONTIERS IN PHYSIOLOGY (2019)
Exercise ameliorates the FGF21-adiponectin axis impairment in diet-induced obese mice
Wenqi Yang et al.
ENDOCRINE CONNECTIONS (2019)
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
Rohit Loomba et al.
GASTROENTEROLOGY (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis
Ishan Lakhani et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases
Jonathan G. Stine et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men
Hirokazu Taniguchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults
Steven C. Moore et al.
JAMA INTERNAL MEDICINE (2016)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy
Jia Liu et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Cardiorespiratory Fitness and Visceral Fat Are Key Determinants of Serum Fibroblast Growth Factor 21 Concentration in Japanese Men
Hirokazu Taniguchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acute Exercise Induces FGF21 Expression in Mice and in Healthy Humans
Kook Hwan Kim et al.
PLOS ONE (2013)
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
S. L. Samson et al.
DIABETOLOGIA (2011)
Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse
Klementina Fon Tacer et al.
MOLECULAR ENDOCRINOLOGY (2010)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease
Joanne B. Krasnoff et al.
HEPATOLOGY (2008)
Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states
Michael K. Badman et al.
CELL METABOLISM (2007)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Physical fitness and activity as separate heart disease risk factors: a meta-analysis
PT Williams
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2001)
Share Paper
